Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/31675
Title: Mechanisms of disease: Macrophage migration inhibitory factor in SLE, RA and atherosclerosis.
Authors: Ayoub S. ;Hickey M.J.;Morand E.F. 
Institution: (Ayoub) Department of Rheumatology, Monash Medical Centre, Monash University, Melbourne, VIC, Australia (Hickey) Centre for Inflammatory Diseases, Monash University, Melbourne, VIC, Australia (Morand) Department of Medicine, Monash University, Monash Medical Centre, Melbourne, VIC, Australia
Issue Date: 16-Oct-2012
Copyright year: 2008
Publisher: Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom)
Place of publication: United Kingdom
Publication information: Nature Clinical Practice Rheumatology. 4 (2) (pp 98-105), 2008. Date of Publication: February 2008.
Abstract: The past decade has seen the emergence of two new paradigms in inflammatory disease: first, cardiovascular complications of atherosclerosis are markedly increased in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE); and second, inflammatory mechanisms are important in the pathogenesis of atherosclerosis. These concurrent developments have lead to the concept that inflammatory mediators operative in RA and SLE might be causal in the accelerated atherosclerosis observed, a concept supported by clinical studies showing that this acceleration is not fully explained by traditional vascular risk factors. Separate lines of evidence implicate the cytokine macrophage migration inhibitory factor (MIF) in RA, SLE, and atherosclerosis. Several reports have revealed definitive in vivo evidence of the activity of MIF in a model of SLE, demonstrated a novel role for MIF in monocyte/macrophage recruitment, and showed that MIF regulates a key mediator of inflammatory cell activation. Together with evidence that MIF circulates in increased concentrations in patients with RA and SLE, this information suggests that in addition to contributing to each disease, MIF might contribute directly to the acceleration of atherosclerosis in RA and SLE.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/ncprheum0701
PubMed URL: 18235539 [http://www.ncbi.nlm.nih.gov/pubmed/?term=18235539]
ISSN: 1745-8382
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/31675
Type: Review
Type of Clinical Study or Trial: Review article (e.g. literature review, narrative review)
Appears in Collections:Articles

Show full item record

Page view(s)

34
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.